Aardvark Therapeutics Faces Securities Fraud Investigation
The Law Offices of Frank R. Cruz issued notices announcing securities-fraud investigations into Aardvark Therapeutics after a February pause of its HERO trial and a May FDA clinical-hold, with stock declines highlighting investor concerns. The firm also announced a probe into Taboola following its August 5, 2026 earnings report that missed guidance, prompting a sharp stock drop. Separately, Glancy Prongay Wolke & Rotter LLP announced an investigation into Parsons Corporation after its July 29, 2026 results revealed a $77 million loss on two nonstrategic contracts, contributing to a significant share decrease. Rollins, Inc. became another focus after July 22, 2026 earnings showed margin and cash-flow declines, with investors reacting to CEO comments about weaker lead generation. A fifth investigation concerns Replimune Group after the FDA’s July 28 briefing deemed RP1 data not interpretable, sending the stock sharply lower on the same day. These actions illustrate ongoing investor-protection efforts by multiple law firms amid corporate earnings disappointments and regulatory concerns.
How it spread

